Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels

AIDS

Volumn 16, Issue 7, 2002, Pages 973-982

  Røge, Birgit T ^a   Calbet, José A L ^a   Møller, Kirsten ^a   Ullum, Henrik ^a   Hendel, Helle W ^a   Gerstoft, Jan ^a   Pedersen, Bente K ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Exercise; HIV; Hyperlactatemia; Lipodystrophy; Mitochondrial toxicity; Nucleoside analogues; Oxygen consumption

Indexed keywords

ACYL COENZYME A; ANTIRETROVIRUS AGENT; CITRATE SYNTHASE; GLYCOGEN; LACTIC ACID; NUCLEOSIDE ANALOG; NUCLEOTIDE; OXIDOREDUCTASE;

ADULT; AGED; ARTICLE; BLOOD GAS ANALYSIS; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERLACTATEMIA; LIPODYSTROPHY; MALE; MUSCLE BIOPSY; MUSCLE MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SKELETAL MUSCLE; WORKLOAD;

3-HYDROXYACYL COA DEHYDROGENASES; ACIDOSIS, LACTIC; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOPSY; BODY COMPOSITION; CITRATE (SI)-SYNTHASE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; GLYCOGEN; HIV INFECTIONS; HUMANS; LACTATES; LIPODYSTROPHY; MALE; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; NUCLEOTIDES; OXYGEN CONSUMPTION; PYRUVATES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037013087     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205030-00003     Document Type: Article

References (44)

1. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: A case report
2. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine
3. Lactic acidosis associated with stavudine administration: A report of five cases
4. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy
5. Screening for nucleoside-associated lactic acidosis
6. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
7. The occurence of hyperlactatemia in HIV-infected patients on NRTI treatment
8. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
9. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
10. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
11. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
12. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors
13. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
14. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
15. Multiple symmetric lipomatosis: Abnormalities in complex IV and multiple deletions in mitochondrial DNA
16. Single large-scale mitochondrial DNA deletion in a patient with mitochondrial myopathy associated with multiple symmetric lipomatosis
17. Defects of mitochondrial respiratory chain in multiple symmetric lipomatosis
18. Diseases of the mitochondrial DNA
19. Anaerobic threshold as detected from ventilatory and metabolic exercise responses in patients with mitochondrial respiratory chain defect
20. The anaerobic threshold: Definition, physiological significance and identification
21. Fat distribution and metabolic changes in patients with HIV infection
22. Blood lactate during exercise: Time course of training adaptation in humans
23. Effect of training on blood lactate levels during submaximal exercise
24. Limiting factors for maximum oxygen uptake and determinants of endurance performance
25. Time course of the adaptive responses of aerobic power and heart rate to training
26. 2max and ventilatory threshold responses to endurance training
27. Mitochondrial enzyme deficiency causing exercise limitation in normal-appearing adults
28. Skeletal muscle substrate metabolism during exercise: Methodological considerations
29. Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids
30. Lactate elimination in man: Effects of lactate concentration and hepatic dysfunction
31. Contribution of liver and skeletal muscle to alanine and lactate metabolism in humans
32. Physiologic hyperinsulinemia stimulates lactate extraction by heart muscle in the conscious dog
33. Renal glucose production during insulin-induced hypoglycemia
34. Renal substrate metabolism and gluconeogenesis during hypoglycemia in humans
35. Disturbances of lactate metabolism in patients with liver damage due to paracetamol overdose
36. Prolongation of the half-life of lactate after maximal exercise in patients with hepatic dysfunction
37. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion
38. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells
39. AZT decreases rat myocardial cytochrome oxidase activity and increases beta-myosin heavy chain content
40. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC) on cultured human muscle cells
41. mtDNA depletion with variable tissue expression: A novel genetic abnormality in mitochondrial diseases
42. Effect of epinephrine on muscle glycogenolysis and insulin-stimulated muscle glycogen synthesis in humans
43. Syndrome of body fat redistribution in HIV-1-infected patients: Relationships to cortisol and catecholamines